Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists track tumor evolution under immune attack in tiny study

NCT ID NCT02724488

Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study looks at how tumors evolve when treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers will take blood samples and tumor biopsies from 14 people with advanced head and neck cancer or melanoma to track genetic changes. The goal is to understand why some tumors become resistant to treatment, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors understand why some tumors stop responding to immune therapies, potentially guiding future treatment strategies.
What could go wrong
This is a very small, early-stage observational study with only 14 participants, so results may not apply broadly. It is designed to gather knowledge, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

14 people

The number who actually took part.

Start date

Apr 2015

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

PART 1: Patients with a histological or cytological diagnosis of advanced solid tumors who are currently on immune checkpoint inhibitors; fulfill criteria for blood sample collection; and provided written voluntary informed consent. PART 2: Patients with a histological or cytological diagnosis of advanced solid tumors who are candidates for a phase I, II, or III clinical trial testing immune checkpoint inhibitors or planning to have treatment with ICIs or other immunological therapy as standard of care; have at least one biopsiable lesion deemed accessible and safe to biopsy; fulfill our institution's laboratory parameters for tumor biopsy, and provided written voluntary informed consent.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PART 1: Inclusion Criteria: 1. Age \> 18 years. 2. Histological or cytological proof of metastatic solid tumors. 3. Currently receiving immune checkpoint inhibitors or other immunologic therapies of interest (to be determined by study principal investigators). 4. Willingness and ability of patient to provide signed voluntary informed consent. Exclusion Criteria: 1. Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment. 2. Any contraindication to undergoing a venepuncture. PART 2: Inclusion Criteria: 1. Age \> 18 years. 2. Histological or cytological proof of metastatic solid tumors. 3. At least one biopsiable lesion deemed medically accessible and safe to biopsy. 4. Candidate for one or more phase I or II or III clinical trials with immune checkpoint inhibitors at the time of study enrolment. Patients receiving approved immune checkpoint inhibitors or via special access are also eligible. Patients receiving other immunologic therapies of interest may be allowed (to be determined by study principal investigators). 5. Fulfills local institution's laboratory parameters for tumor biopsy. 6. Willingness and ability of patient to provide signed voluntary informed consent. Exclusion Criteria: 1. Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment. 2. Any contraindication to undergoing a biopsy procedure. 3. Any contraindication to undergoing a venepuncture.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms melanoma metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancer Melanoma

More trials for these conditions

Other studies related to the condition(s) this trial covers.